Zipprick Jenny, Demir Enes, Krynska Hanna, Köprülüoğlu Sıla, Strauß Katharina, Skribek Marcus, Hutyra-Gram Ötvös Rita, Gad Annica K B, Dobra Katalin
Department of Oncology-Pathology, Karolinska Institutet, 171 77 Solna, Sweden.
Cancers (Basel). 2025 Mar 14;17(6):986. doi: 10.3390/cancers17060986.
: Non-small cell lung cancer and pleural mesothelioma are among the most lethal and therapy-resistant tumors in humans. These tumors are diagnosed late, frequently present pleural effusion and develop drug resistance, and the treatment is often inefficient and largely alliative. Therefore, there is an urgent need to refine the selection of drugs and patients for personalized treatment. : To progress the field, we performed a systematic literature review in line with the PRISMA guidelines followed by a narrative synthesis approach to identify themes. : The literature to date shows, in general, a positive correlation between the drug-sensitivity of patient-derived cells ex vivo and the clinical outcome. However, only a handful of these studies show a numerical correlation. This, along with the vast diversity of correlated techniques and parameters makes it difficult to directly compare the findings. To build a common knowledge base for future studies, we therefore offer a comprehensive summary of the literature, identify gaps, and suggest future avenues for research. : We present unified recommendations for the collection, preparation, and ex vivo sensitivity testing of samples for the future development of personalized medicine.
非小细胞肺癌和胸膜间皮瘤是人类最致命且具有治疗抗性的肿瘤之一。这些肿瘤诊断较晚，常出现胸腔积液并产生耐药性，治疗往往效果不佳且主要是姑息性的。因此，迫切需要优化药物和患者的选择以进行个性化治疗。
为推动该领域发展，我们按照PRISMA指南进行了系统的文献综述，随后采用叙述性综合方法来确定主题。
迄今为止的文献总体表明，体外患者来源细胞的药物敏感性与临床结果之间存在正相关。然而，这些研究中只有少数显示出数值相关性。这一点，再加上相关技术和参数的巨大多样性，使得难以直接比较研究结果。因此，为了为未来研究建立一个共同的知识库，我们对文献进行了全面总结，找出差距，并提出未来的研究方向。
我们针对个性化医疗的未来发展，对样本的采集、制备和体外敏感性测试提出统一建议。
